A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor- at the translational level

Author： Nakazato H.   Oku H.   Yamane S.   Tsuruta Y.   Suzuki R.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.446, Iss.1, 2002-06, pp. : 177-185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pirfenidone: A Novel Anti-fibrotic Agent and Progressive Chronic Allograft Rejection

By Dosanjh A.   Ikonen T.   Wan B.   Morris R.E.  

Pulmonary Pharmacology & Therapeutics, Vol. 15, Iss. 5, 2002-10 ,pp. : 433-437

Academic Press

Access to resources Recommend Favorite

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

By Cho Monique E   Kopp Jeffrey B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 275-283

Informa Healthcare

Access to resources Recommend Favorite

Pirfenidone suppresses tumor necrosis factor- , enhances interleukin-10 and protects mice from endotoxic shock

By Oku H.   Nakazato H.   Horikawa T.   Tsuruta Y.   Suzuki R.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 167-176

Elsevier

Access to resources Recommend Favorite

CCN2: a novel, specific and valid target for anti-fibrotic drug intervention

By Leask Andrew  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1067-1071

Informa Healthcare

Access to resources Recommend Favorite

Clinical images: Multi‐modality imaging monitoring of anti–tumor necrosis factor α treatment at the joint and skin level in psoriatic arthritis

By  

Arthritis & Rheumatism, Vol. 62, Iss. 12, 2010-12 ,pp. : 3829-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite